Poziotinib Induces Responses in EGFR Exon 20+ NSCLC - Episode 4

Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

September 12, 2022

Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.

EP. 1: Poziotinib Elicits Encouraging Responses in EGFR Exon 20–Mutated NSCLC

EP. 2: Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

EP. 3: Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

Now Viewing

EP. 4: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC

Welcome to OncLive On Air^®! I’m your host today, Ryan Scott.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Yasir Y. Elamin, MD, an assistant professor in the Department of Thoracic/Head and Neck Medical Oncology and the Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center. Dr Elamin highlighted the results from a phase 2 study (NCT03066206) that evaluated the clinical efficacy and resistance mechanisms of poziotinib and effects of insertion location on the agent's efficacy in EGFR exon 20–mutant non–small cell lung cancer (NSCLC).

The study found that poziotinib yielded a 32% response rate in EGFR exon 20–mutant NSCLC and suggested that poziotinib sensitivity is highly dependent on insertion location.

In our exclusive interview, Dr Elamin expanded on the key data found with the use of poziotinib in patients with EGFR exon 20–mutant NSCLC.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.